Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3,

Slides:

Advertisements

Similar presentations

Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.

Advertisements

HCL Patient Seminar September 2014 Quality of Life Monica Else.

Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,

Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.

Overview Diagnosis & Treatment

S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.

Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis Gastroenterology 2015, /j.gastro

THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.

Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.

Differences between radiology and histopathology: Are we judging correctly? Simona Onali 1, Emmanuel Tsochatzis 1, James O’Beirne 1, Aileen Marshall 1,

Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.

HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,

Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.

CLINICAL COURSE AND MANAGEMENT OF NOROVIRUS INFECTION FOLLOWING SMALL BOWEL TRANSPLANTATION IN CHILDREN K. Nikaki¹, M. Patel², J. Hartley¹, L. Ibarra³,

Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.

Should it be viewed as a single entity? Hypersensitivity pneumonitis Should it be viewed as a single entity? Venerino Poletti versus Athol Wells.

The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.

Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Budesonide induces remission more effectively than Prednisone in a controlled trial of patients with Autoimmune Hepatitis GASTROENTEROLOGY 2010;139:1198–1206.

TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

UK Hospitalizations due to Stroke in Prostate Cancer Patients

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Are illness perceptions a predictor of quality of life in epilepsy and psychogenic non-epileptic seizures ? Gregg Rawlings, Markus Reuber

129 patients with chronic hepatitis C

Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP

Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.

DIFFERENCE IS SIGNIFICANT

SMOKING AND HISTOLOGICAL STAGE OF CHRONIC VIRAL HEPATITIS

4th IAS Conference , Sydney, Australia, July 2007

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.

Indeterminate and inconclusive results are common when using Interferon Gamma Release Assay as screening for TB in patients with IBD Nasr I, Goel RM, Ward.

Long-term impact of response to interferon-based therapy in patients with chronic HCV in relation to liver function, survival and cause of death Philip.

Carbon fibre cage versus autograft for anterior cervical discectomy and inter-body fusion M Taha, J Tapendin, N Alam, A Kemeny, M Radatz Department of.

Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.

HCV & liver transplantation

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

BACKGROUND MATERIALS & METHODS RESULTS CONCLUSIONS

Clinical features of resected hepatocellular carcinoma emerging after sustained virological response against chronic hepatitis C Hepato-biliary-pancreatic.

Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk M.A. Little, P. Dupont, E. Campbell,

Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2

Figure 7 Management algorithm for patients with ACLF

Volume 144, Issue 3, Pages e7 (March 2013)

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5 year open-label follow-up study Martin Gerbert,

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Autoimmune hepatitis Journal of Hepatology

Clinical outcome after SVR: ANRS CO22 HEPATHER

Autoimmune hepatitis: A life-long disease

Impact of metabolic risk factors on HCC

From non-A, non-B hepatitis to hepatitis C virus cure

Hepatitis C: After the Diagnosis

Volume 149, Issue 2, Pages (August 2015)

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B Eugene R. Schiff, Samuel S.

Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients Sven M.A. Francque, An Verrijken, Ilse Mertens, Guy Hubens,

Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis Jean–François Dufour, Carl M. Oneta, Jean–Jacques.

Volume 141, Issue 4, Pages e3 (October 2011)

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis Arun J. Sanyal, Pouneh S. Mofrad, Melissa.

Selonsertib in NASH: phase 2

Persistent histological inflammation in autoimmune hepatitis despite

Volume 54, Issue 2, Pages (February 2011)

Volume 126, Issue 7, Pages (June 2004)

GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR

Coiffier B et al. Proc ASH 2011;Abstract 265.

Clinical, dermatoscopical and histopathological correlation of atypical actinic keratoses ID21905 Alise Balcere1, Raimonds Karls, Māris Sperga1, Māra Rone.

METABOLIC CHANGES AFTER VIRAL ERADICATION IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION Tudor Cuciureanu1,2, Laura Huiban1,2, Stefan Chiriac1,2.

Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk M.A. Little, P. Dupont, E. Campbell,

Presentation transcript:

Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3, E.McFarlane1, D. Gleeson1. 1Liver Unit and 3 Histopathology Department, Royal Hallamshire Hospital, Sheffield, UK. 2Gastroenterology Department, Rotherham General Hospital, Rotherham, UK Introduction: A link between steatosis and Prednisolone therapy has been suggested, but is poorly documented. In Hepatitis C, steatosis is associated with genotype 3, high viral replication, poor response to treatment and fibrosis proression. Little is known about steatosis in Autoimmune Hepatitis (AIH). Results 2: On biopsy in remission, 50 of the 109 patients had steatosis, which had appeared or worsened in 35 patients. In 6 patients steatosis disappeared and 31 patients developed new steatosis. Steatosis grade worsened between diagnostic and follow up biopsy (p<0.001 by M-W). Worsening of steatosis was not related to gender, age, diabetes, or body weight or to duration, initial dose or maintenance dose of Prednisolone. Results 3: Fibrosis score improved with treatment in the cohort as a whole (p<0.01). Although improvement was less in patients with worsening steatosis (n=31), compared to those with stable steatosis (n=76), the difference was not significant. On regression analysis, change in fibrosis score with treatment was associated with NI score on follow-up biopsy (<0.0001) and with Body Weight (P=0.046) but not with either presence or worsening of steatosis. Aim: To assess the prevalence, progression and significance of steatosis in AIH. Patients and methods: 109 patients with AIH, 18 men, median age 53 (9 -85) years, 37 probable, 75 definite by IAIHG criteria. We assessed steatosis (grade 1-3 and distribution), Ishak necro-inflammatory (NI) score and Ishak fibrosis score in paired liver biopsies: the initial diagnostic biopsy and a follow up biopsy when in remission after median 25 (3-115) months Prednisolone. Inter-group comparison (Mann-Whitney test) and Cox regression analysis were performed using SPSS. Results 1: Comparison of patients with and without steatosis on initial biopsy. Range(median) Fibrosis stage on remission biopsy was associated with fibrosis stage on initial biopsy (p<0.001) and with NI score on remission biopsy (p<0.001) . The association with worsening steatosis, reported in abstract was no longer significant. No steatosis N=84 Steatosis N=25 P value Age 9-77 (48) 20-84 (58) P=0.005 NI score 1-18 (12) 1-17 (8) P=0.002 Diabetes 10 (12%) 12 (48%) P=0.00 IAIHG score 11-25 (17) 13-24 (16) P=0.950 Histology AIH grade 0-5 (4) -2-5 (3) P=0.094 Weight 37.1-168(68.1) 50-98.1(70) P=0.641 Fibrosis 0-6 (3) P=0.394 Conclusions: Steatosis is found in ¼ of patients with AIH and is related to age and diabetes. Steatosis worsens in 1/3 of patients treated with Prednisolone. There was no association with dose or duration of Prednisolone. There was no significant association with fibrosis progression.